nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—ABCG2—Cladribine—multiple sclerosis	0.0516	0.152	CbGbCtD
Nilotinib—ABCG2—Mitoxantrone—multiple sclerosis	0.0376	0.111	CbGbCtD
Nilotinib—CYP2D6—Fingolimod—multiple sclerosis	0.0272	0.08	CbGbCtD
Nilotinib—ABCG2—Dexamethasone—multiple sclerosis	0.0195	0.0574	CbGbCtD
Nilotinib—ABCB1—Methylprednisolone—multiple sclerosis	0.0186	0.0547	CbGbCtD
Nilotinib—CYP3A4—Fingolimod—multiple sclerosis	0.0173	0.0509	CbGbCtD
Nilotinib—ABCG2—Methotrexate—multiple sclerosis	0.0157	0.0461	CbGbCtD
Nilotinib—CYP2B6—Dexamethasone—multiple sclerosis	0.0137	0.0403	CbGbCtD
Nilotinib—ABCB1—Mitoxantrone—multiple sclerosis	0.0136	0.0399	CbGbCtD
Nilotinib—ABCB1—Betamethasone—multiple sclerosis	0.0121	0.0356	CbGbCtD
Nilotinib—ABCB1—Prednisolone—multiple sclerosis	0.0119	0.0351	CbGbCtD
Nilotinib—ABCB1—Prednisone—multiple sclerosis	0.0113	0.0331	CbGbCtD
Nilotinib—CYP3A4—Methylprednisolone—multiple sclerosis	0.0111	0.0328	CbGbCtD
Nilotinib—CYP2C8—Dexamethasone—multiple sclerosis	0.0104	0.0306	CbGbCtD
Nilotinib—CYP3A4—Triamcinolone—multiple sclerosis	0.00845	0.0248	CbGbCtD
Nilotinib—CYP3A4—Mitoxantrone—multiple sclerosis	0.00813	0.0239	CbGbCtD
Nilotinib—CYP2C9—Dexamethasone—multiple sclerosis	0.00725	0.0213	CbGbCtD
Nilotinib—CYP3A4—Betamethasone—multiple sclerosis	0.00725	0.0213	CbGbCtD
Nilotinib—CYP3A4—Prednisolone—multiple sclerosis	0.00715	0.021	CbGbCtD
Nilotinib—ABCB1—Dexamethasone—multiple sclerosis	0.00703	0.0207	CbGbCtD
Nilotinib—CYP3A4—Prednisone—multiple sclerosis	0.00675	0.0199	CbGbCtD
Nilotinib—CYP2D6—Dexamethasone—multiple sclerosis	0.00663	0.0195	CbGbCtD
Nilotinib—ABCB1—Methotrexate—multiple sclerosis	0.00565	0.0166	CbGbCtD
Nilotinib—CYP3A4—Dexamethasone—multiple sclerosis	0.00421	0.0124	CbGbCtD
Nilotinib—EPHB3—nerve—multiple sclerosis	0.00336	0.0256	CbGeAlD
Nilotinib—EPHA4—nerve—multiple sclerosis	0.00281	0.0214	CbGeAlD
Nilotinib—EPHB2—brainstem—multiple sclerosis	0.00219	0.0167	CbGeAlD
Nilotinib—EPHB2—retina—multiple sclerosis	0.00211	0.0161	CbGeAlD
Nilotinib—CDC42BPB—retina—multiple sclerosis	0.00187	0.0142	CbGeAlD
Nilotinib—EPHA3—retina—multiple sclerosis	0.00177	0.0135	CbGeAlD
Nilotinib—MAPK8—brainstem—multiple sclerosis	0.00175	0.0133	CbGeAlD
Nilotinib—MAPK8—retina—multiple sclerosis	0.00169	0.0128	CbGeAlD
Nilotinib—CA1—nerve—multiple sclerosis	0.00156	0.0118	CbGeAlD
Nilotinib—MAP4K1—retina—multiple sclerosis	0.00154	0.0117	CbGeAlD
Nilotinib—EPHB3—brainstem—multiple sclerosis	0.00144	0.011	CbGeAlD
Nilotinib—CDC42BPB—medulla oblongata—multiple sclerosis	0.00135	0.0103	CbGeAlD
Nilotinib—CDC42BPB—midbrain—multiple sclerosis	0.00123	0.00938	CbGeAlD
Nilotinib—MAPK8—medulla oblongata—multiple sclerosis	0.00122	0.00928	CbGeAlD
Nilotinib—CA4—nerve—multiple sclerosis	0.00122	0.00925	CbGeAlD
Nilotinib—EPHA4—brainstem—multiple sclerosis	0.00121	0.00917	CbGeAlD
Nilotinib—CDC42BPB—spinal cord—multiple sclerosis	0.0012	0.00915	CbGeAlD
Nilotinib—EPHB2—nervous system—multiple sclerosis	0.00115	0.00872	CbGeAlD
Nilotinib—MAPK8—midbrain—multiple sclerosis	0.00112	0.00848	CbGeAlD
Nilotinib—MAPK14—brainstem—multiple sclerosis	0.00111	0.00845	CbGeAlD
Nilotinib—EPHB2—central nervous system—multiple sclerosis	0.00111	0.0084	CbGeAlD
Nilotinib—EPHA8—nervous system—multiple sclerosis	0.0011	0.00836	CbGeAlD
Nilotinib—MAPK8—spinal cord—multiple sclerosis	0.00109	0.00828	CbGeAlD
Nilotinib—EPHA8—central nervous system—multiple sclerosis	0.00106	0.00805	CbGeAlD
Nilotinib—EPHA8—cerebellum—multiple sclerosis	0.00104	0.00787	CbGeAlD
Nilotinib—MAPK11—nervous system—multiple sclerosis	0.00102	0.00778	CbGeAlD
Nilotinib—CDC42BPB—nervous system—multiple sclerosis	0.00101	0.00771	CbGeAlD
Nilotinib—MAPK11—central nervous system—multiple sclerosis	0.000985	0.00749	CbGeAlD
Nilotinib—CDC42BPB—central nervous system—multiple sclerosis	0.000977	0.00743	CbGeAlD
Nilotinib—MAPK11—cerebellum—multiple sclerosis	0.000963	0.00732	CbGeAlD
Nilotinib—EPHA3—nervous system—multiple sclerosis	0.000962	0.00731	CbGeAlD
Nilotinib—CDC42BPB—cerebellum—multiple sclerosis	0.000955	0.00726	CbGeAlD
Nilotinib—BRAF—midbrain—multiple sclerosis	0.000928	0.00705	CbGeAlD
Nilotinib—EPHA3—central nervous system—multiple sclerosis	0.000926	0.00704	CbGeAlD
Nilotinib—HCK—medulla oblongata—multiple sclerosis	0.000926	0.00704	CbGeAlD
Nilotinib—MAPK8—nervous system—multiple sclerosis	0.000918	0.00697	CbGeAlD
Nilotinib—EPHA6—nervous system—multiple sclerosis	0.000918	0.00697	CbGeAlD
Nilotinib—EPHB3—spinal cord—multiple sclerosis	0.000898	0.00683	CbGeAlD
Nilotinib—MAPK8—central nervous system—multiple sclerosis	0.000884	0.00672	CbGeAlD
Nilotinib—EPHA6—central nervous system—multiple sclerosis	0.000884	0.00672	CbGeAlD
Nilotinib—EPHB2—brain—multiple sclerosis	0.000877	0.00667	CbGeAlD
Nilotinib—MAPK8—cerebellum—multiple sclerosis	0.000864	0.00656	CbGeAlD
Nilotinib—LYN—nervous system—multiple sclerosis	0.000847	0.00644	CbGeAlD
Nilotinib—HCK—midbrain—multiple sclerosis	0.000846	0.00643	CbGeAlD
Nilotinib—EPHA4—medulla oblongata—multiple sclerosis	0.000841	0.00639	CbGeAlD
Nilotinib—EPHA8—brain—multiple sclerosis	0.000841	0.00639	CbGeAlD
Nilotinib—CA7—midbrain—multiple sclerosis	0.000828	0.00629	CbGeAlD
Nilotinib—HCK—spinal cord—multiple sclerosis	0.000825	0.00627	CbGeAlD
Nilotinib—MAP2K5—brainstem—multiple sclerosis	0.000825	0.00627	CbGeAlD
Nilotinib—LYN—central nervous system—multiple sclerosis	0.000815	0.0062	CbGeAlD
Nilotinib—TIE1—nervous system—multiple sclerosis	0.000796	0.00605	CbGeAlD
Nilotinib—MAPK11—brain—multiple sclerosis	0.000782	0.00594	CbGeAlD
Nilotinib—CDC42BPB—brain—multiple sclerosis	0.000776	0.0059	CbGeAlD
Nilotinib—TIE1—central nervous system—multiple sclerosis	0.000766	0.00582	CbGeAlD
Nilotinib—EPHB3—nervous system—multiple sclerosis	0.000757	0.00575	CbGeAlD
Nilotinib—CA14—medulla oblongata—multiple sclerosis	0.000755	0.00573	CbGeAlD
Nilotinib—TIE1—cerebellum—multiple sclerosis	0.000749	0.00569	CbGeAlD
Nilotinib—EPHB2—Diflorasone—Methylprednisolone—multiple sclerosis	0.000738	0.174	CbGdCrCtD
Nilotinib—EPHB4—medulla oblongata—multiple sclerosis	0.000735	0.00559	CbGeAlD
Nilotinib—EPHA3—brain—multiple sclerosis	0.000735	0.00559	CbGeAlD
Nilotinib—KIT—brainstem—multiple sclerosis	0.000731	0.00556	CbGeAlD
Nilotinib—EPHB3—central nervous system—multiple sclerosis	0.000729	0.00554	CbGeAlD
Nilotinib—EPHB2—Diflorasone—Dexamethasone—multiple sclerosis	0.000727	0.172	CbGdCrCtD
Nilotinib—EPHB2—Diflorasone—Betamethasone—multiple sclerosis	0.000727	0.172	CbGdCrCtD
Nilotinib—BRAF—cerebellum—multiple sclerosis	0.000718	0.00546	CbGeAlD
Nilotinib—EPHB3—cerebellum—multiple sclerosis	0.000712	0.00541	CbGeAlD
Nilotinib—EPHB2—Diflorasone—Triamcinolone—multiple sclerosis	0.00071	0.168	CbGdCrCtD
Nilotinib—TEK—medulla oblongata—multiple sclerosis	0.000704	0.00535	CbGeAlD
Nilotinib—EPHA6—brain—multiple sclerosis	0.000701	0.00533	CbGeAlD
Nilotinib—MAPK8—brain—multiple sclerosis	0.000701	0.00533	CbGeAlD
Nilotinib—HCK—nervous system—multiple sclerosis	0.000695	0.00529	CbGeAlD
Nilotinib—MAPK14—spinal cord—multiple sclerosis	0.000692	0.00526	CbGeAlD
Nilotinib—CA14—midbrain—multiple sclerosis	0.00069	0.00524	CbGeAlD
Nilotinib—EPHB2—Diflorasone—Prednisone—multiple sclerosis	0.000674	0.159	CbGdCrCtD
Nilotinib—CA14—spinal cord—multiple sclerosis	0.000673	0.00511	CbGeAlD
Nilotinib—EPHB6—medulla oblongata—multiple sclerosis	0.000673	0.00511	CbGeAlD
Nilotinib—EPHB4—midbrain—multiple sclerosis	0.000672	0.00511	CbGeAlD
Nilotinib—HCK—central nervous system—multiple sclerosis	0.00067	0.00509	CbGeAlD
Nilotinib—EPHB2—Diflorasone—Prednisolone—multiple sclerosis	0.000658	0.155	CbGdCrCtD
Nilotinib—EPHB4—spinal cord—multiple sclerosis	0.000656	0.00498	CbGeAlD
Nilotinib—ABL2—cerebellum—multiple sclerosis	0.00065	0.00494	CbGeAlD
Nilotinib—LYN—brain—multiple sclerosis	0.000647	0.00492	CbGeAlD
Nilotinib—TEK—midbrain—multiple sclerosis	0.000643	0.00489	CbGeAlD
Nilotinib—CA7—cerebellum—multiple sclerosis	0.00064	0.00487	CbGeAlD
Nilotinib—MAP4K1—brain—multiple sclerosis	0.000638	0.00485	CbGeAlD
Nilotinib—ABL1—brainstem—multiple sclerosis	0.000636	0.00484	CbGeAlD
Nilotinib—EPHA4—nervous system—multiple sclerosis	0.000632	0.0048	CbGeAlD
Nilotinib—TEK—spinal cord—multiple sclerosis	0.000628	0.00477	CbGeAlD
Nilotinib—CA3—nervous system—multiple sclerosis	0.000624	0.00475	CbGeAlD
Nilotinib—EPHB6—midbrain—multiple sclerosis	0.000615	0.00467	CbGeAlD
Nilotinib—ABL1—retina—multiple sclerosis	0.000614	0.00467	CbGeAlD
Nilotinib—EPHA4—central nervous system—multiple sclerosis	0.000609	0.00463	CbGeAlD
Nilotinib—TIE1—brain—multiple sclerosis	0.000608	0.00462	CbGeAlD
Nilotinib—CA3—central nervous system—multiple sclerosis	0.000601	0.00457	CbGeAlD
Nilotinib—EPHB6—spinal cord—multiple sclerosis	0.0006	0.00456	CbGeAlD
Nilotinib—EPHA4—cerebellum—multiple sclerosis	0.000595	0.00452	CbGeAlD
Nilotinib—BRAF—brain—multiple sclerosis	0.000583	0.00443	CbGeAlD
Nilotinib—MAPK14—nervous system—multiple sclerosis	0.000583	0.00443	CbGeAlD
Nilotinib—FGR—nervous system—multiple sclerosis	0.00058	0.00441	CbGeAlD
Nilotinib—EPHB3—brain—multiple sclerosis	0.000578	0.0044	CbGeAlD
Nilotinib—MAP2K5—medulla oblongata—multiple sclerosis	0.000575	0.00437	CbGeAlD
Nilotinib—PDGFRA—spinal cord—multiple sclerosis	0.000569	0.00432	CbGeAlD
Nilotinib—CA9—cerebellum—multiple sclerosis	0.000562	0.00428	CbGeAlD
Nilotinib—CSF1R—medulla oblongata—multiple sclerosis	0.000561	0.00427	CbGeAlD
Nilotinib—MAPK14—central nervous system—multiple sclerosis	0.000561	0.00426	CbGeAlD
Nilotinib—FGR—central nervous system—multiple sclerosis	0.000559	0.00425	CbGeAlD
Nilotinib—MAPK14—cerebellum—multiple sclerosis	0.000548	0.00417	CbGeAlD
Nilotinib—EPHA2—nervous system—multiple sclerosis	0.000542	0.00412	CbGeAlD
Nilotinib—CA14—cerebellum—multiple sclerosis	0.000534	0.00405	CbGeAlD
Nilotinib—HCK—brain—multiple sclerosis	0.000532	0.00404	CbGeAlD
Nilotinib—TEK—nervous system—multiple sclerosis	0.000529	0.00402	CbGeAlD
Nilotinib—ABL2—brain—multiple sclerosis	0.000528	0.00402	CbGeAlD
Nilotinib—MAP2K5—midbrain—multiple sclerosis	0.000526	0.004	CbGeAlD
Nilotinib—CA4—brainstem—multiple sclerosis	0.000523	0.00397	CbGeAlD
Nilotinib—EPHA2—central nervous system—multiple sclerosis	0.000522	0.00397	CbGeAlD
Nilotinib—CA7—brain—multiple sclerosis	0.00052	0.00395	CbGeAlD
Nilotinib—EPHB4—cerebellum—multiple sclerosis	0.00052	0.00395	CbGeAlD
Nilotinib—CSF1R—midbrain—multiple sclerosis	0.000513	0.0039	CbGeAlD
Nilotinib—MAP2K5—spinal cord—multiple sclerosis	0.000513	0.0039	CbGeAlD
Nilotinib—KIT—medulla oblongata—multiple sclerosis	0.00051	0.00387	CbGeAlD
Nilotinib—TEK—central nervous system—multiple sclerosis	0.000509	0.00387	CbGeAlD
Nilotinib—EPHB6—nervous system—multiple sclerosis	0.000505	0.00384	CbGeAlD
Nilotinib—CSF1R—spinal cord—multiple sclerosis	0.000501	0.0038	CbGeAlD
Nilotinib—PDGFRB—medulla oblongata—multiple sclerosis	0.000498	0.00378	CbGeAlD
Nilotinib—TEK—cerebellum—multiple sclerosis	0.000498	0.00378	CbGeAlD
Nilotinib—EPHB6—central nervous system—multiple sclerosis	0.000487	0.0037	CbGeAlD
Nilotinib—EPHA4—brain—multiple sclerosis	0.000483	0.00367	CbGeAlD
Nilotinib—PDGFRA—nervous system—multiple sclerosis	0.000479	0.00364	CbGeAlD
Nilotinib—CA3—brain—multiple sclerosis	0.000477	0.00363	CbGeAlD
Nilotinib—EPHB6—cerebellum—multiple sclerosis	0.000476	0.00361	CbGeAlD
Nilotinib—KIT—midbrain—multiple sclerosis	0.000466	0.00354	CbGeAlD
Nilotinib—PDGFRA—central nervous system—multiple sclerosis	0.000461	0.00351	CbGeAlD
Nilotinib—PDGFRB—midbrain—multiple sclerosis	0.000455	0.00346	CbGeAlD
Nilotinib—KIT—spinal cord—multiple sclerosis	0.000454	0.00345	CbGeAlD
Nilotinib—PDGFRA—cerebellum—multiple sclerosis	0.000451	0.00343	CbGeAlD
Nilotinib—MAPK14—brain—multiple sclerosis	0.000445	0.00339	CbGeAlD
Nilotinib—PDGFRB—spinal cord—multiple sclerosis	0.000444	0.00337	CbGeAlD
Nilotinib—ABL1—medulla oblongata—multiple sclerosis	0.000444	0.00337	CbGeAlD
Nilotinib—FGR—brain—multiple sclerosis	0.000444	0.00337	CbGeAlD
Nilotinib—CA12—nervous system—multiple sclerosis	0.000442	0.00336	CbGeAlD
Nilotinib—CA14—brain—multiple sclerosis	0.000433	0.00329	CbGeAlD
Nilotinib—CA2—brainstem—multiple sclerosis	0.000433	0.00329	CbGeAlD
Nilotinib—MAP2K5—nervous system—multiple sclerosis	0.000432	0.00328	CbGeAlD
Nilotinib—CA12—central nervous system—multiple sclerosis	0.000426	0.00324	CbGeAlD
Nilotinib—EPHB4—brain—multiple sclerosis	0.000422	0.00321	CbGeAlD
Nilotinib—CSF1R—nervous system—multiple sclerosis	0.000422	0.00321	CbGeAlD
Nilotinib—CA2—retina—multiple sclerosis	0.000418	0.00318	CbGeAlD
Nilotinib—MAP2K5—central nervous system—multiple sclerosis	0.000416	0.00316	CbGeAlD
Nilotinib—CA1—spinal cord—multiple sclerosis	0.000416	0.00316	CbGeAlD
Nilotinib—EPHA2—brain—multiple sclerosis	0.000414	0.00315	CbGeAlD
Nilotinib—MAP2K5—cerebellum—multiple sclerosis	0.000407	0.00309	CbGeAlD
Nilotinib—CSF1R—central nervous system—multiple sclerosis	0.000406	0.00309	CbGeAlD
Nilotinib—ABL1—midbrain—multiple sclerosis	0.000406	0.00308	CbGeAlD
Nilotinib—TEK—brain—multiple sclerosis	0.000404	0.00307	CbGeAlD
Nilotinib—CSF1R—cerebellum—multiple sclerosis	0.000397	0.00302	CbGeAlD
Nilotinib—ABL1—spinal cord—multiple sclerosis	0.000396	0.00301	CbGeAlD
Nilotinib—EPHB6—brain—multiple sclerosis	0.000386	0.00294	CbGeAlD
Nilotinib—KIT—nervous system—multiple sclerosis	0.000383	0.00291	CbGeAlD
Nilotinib—PDGFRB—nervous system—multiple sclerosis	0.000374	0.00284	CbGeAlD
Nilotinib—KIT—central nervous system—multiple sclerosis	0.000369	0.0028	CbGeAlD
Nilotinib—PDGFRA—brain—multiple sclerosis	0.000366	0.00278	CbGeAlD
Nilotinib—CA4—medulla oblongata—multiple sclerosis	0.000364	0.00277	CbGeAlD
Nilotinib—KIT—cerebellum—multiple sclerosis	0.00036	0.00274	CbGeAlD
Nilotinib—PDGFRB—central nervous system—multiple sclerosis	0.00036	0.00274	CbGeAlD
Nilotinib—PDGFRB—cerebellum—multiple sclerosis	0.000352	0.00268	CbGeAlD
Nilotinib—CA1—nervous system—multiple sclerosis	0.00035	0.00266	CbGeAlD
Nilotinib—CA12—brain—multiple sclerosis	0.000338	0.00257	CbGeAlD
Nilotinib—CA1—central nervous system—multiple sclerosis	0.000337	0.00256	CbGeAlD
Nilotinib—ABL1—nervous system—multiple sclerosis	0.000333	0.00253	CbGeAlD
Nilotinib—CA4—midbrain—multiple sclerosis	0.000333	0.00253	CbGeAlD
Nilotinib—MAP2K5—brain—multiple sclerosis	0.00033	0.00251	CbGeAlD
Nilotinib—CA4—spinal cord—multiple sclerosis	0.000325	0.00247	CbGeAlD
Nilotinib—CSF1R—brain—multiple sclerosis	0.000322	0.00245	CbGeAlD
Nilotinib—ABL1—central nervous system—multiple sclerosis	0.000321	0.00244	CbGeAlD
Nilotinib—ABL1—cerebellum—multiple sclerosis	0.000314	0.00238	CbGeAlD
Nilotinib—CA2—medulla oblongata—multiple sclerosis	0.000302	0.0023	CbGeAlD
Nilotinib—KIT—brain—multiple sclerosis	0.000293	0.00222	CbGeAlD
Nilotinib—PDGFRB—brain—multiple sclerosis	0.000286	0.00217	CbGeAlD
Nilotinib—ABCG2—medulla oblongata—multiple sclerosis	0.00028	0.00213	CbGeAlD
Nilotinib—CA2—midbrain—multiple sclerosis	0.000276	0.0021	CbGeAlD
Nilotinib—CYP2D6—brainstem—multiple sclerosis	0.000275	0.00209	CbGeAlD
Nilotinib—CA4—nervous system—multiple sclerosis	0.000274	0.00208	CbGeAlD
Nilotinib—CA2—spinal cord—multiple sclerosis	0.000269	0.00205	CbGeAlD
Nilotinib—CA1—brain—multiple sclerosis	0.000268	0.00203	CbGeAlD
Nilotinib—CA4—central nervous system—multiple sclerosis	0.000264	0.002	CbGeAlD
Nilotinib—CA4—cerebellum—multiple sclerosis	0.000258	0.00196	CbGeAlD
Nilotinib—ABCG2—midbrain—multiple sclerosis	0.000256	0.00194	CbGeAlD
Nilotinib—ABL1—brain—multiple sclerosis	0.000255	0.00194	CbGeAlD
Nilotinib—ABCG2—spinal cord—multiple sclerosis	0.000249	0.0019	CbGeAlD
Nilotinib—CA2—nervous system—multiple sclerosis	0.000227	0.00173	CbGeAlD
Nilotinib—CA2—central nervous system—multiple sclerosis	0.000219	0.00166	CbGeAlD
Nilotinib—CA2—cerebellum—multiple sclerosis	0.000214	0.00162	CbGeAlD
Nilotinib—CA4—brain—multiple sclerosis	0.000209	0.00159	CbGeAlD
Nilotinib—ABCG2—cerebellum—multiple sclerosis	0.000198	0.0015	CbGeAlD
Nilotinib—CYP2B6—nervous system—multiple sclerosis	0.000194	0.00147	CbGeAlD
Nilotinib—ABCB1—retina—multiple sclerosis	0.000191	0.00145	CbGeAlD
Nilotinib—CYP2B6—central nervous system—multiple sclerosis	0.000187	0.00142	CbGeAlD
Nilotinib—CA2—brain—multiple sclerosis	0.000174	0.00132	CbGeAlD
Nilotinib—CYP2C8—brain—multiple sclerosis	0.000165	0.00126	CbGeAlD
Nilotinib—ABCG2—brain—multiple sclerosis	0.000161	0.00122	CbGeAlD
Nilotinib—CYP2B6—brain—multiple sclerosis	0.000148	0.00113	CbGeAlD
Nilotinib—CYP3A4—nervous system—multiple sclerosis	0.000146	0.00111	CbGeAlD
Nilotinib—CYP2D6—nervous system—multiple sclerosis	0.000144	0.0011	CbGeAlD
Nilotinib—CYP3A4—central nervous system—multiple sclerosis	0.000141	0.00107	CbGeAlD
Nilotinib—CYP2D6—central nervous system—multiple sclerosis	0.000139	0.00105	CbGeAlD
Nilotinib—ABCB1—medulla oblongata—multiple sclerosis	0.000138	0.00105	CbGeAlD
Nilotinib—CYP2D6—cerebellum—multiple sclerosis	0.000136	0.00103	CbGeAlD
Nilotinib—ABCB1—midbrain—multiple sclerosis	0.000126	0.000958	CbGeAlD
Nilotinib—ABCB1—spinal cord—multiple sclerosis	0.000123	0.000935	CbGeAlD
Nilotinib—CYP2D6—brain—multiple sclerosis	0.00011	0.000837	CbGeAlD
Nilotinib—ABCB1—nervous system—multiple sclerosis	0.000104	0.000788	CbGeAlD
Nilotinib—ABCB1—central nervous system—multiple sclerosis	9.98e-05	0.000759	CbGeAlD
Nilotinib—Shock—Methylprednisolone—multiple sclerosis	9.77e-05	0.000369	CcSEcCtD
Nilotinib—ABCB1—cerebellum—multiple sclerosis	9.76e-05	0.000741	CbGeAlD
Nilotinib—Hepatobiliary disease—Methotrexate—multiple sclerosis	9.75e-05	0.000368	CcSEcCtD
Nilotinib—Nervous system disorder—Methylprednisolone—multiple sclerosis	9.74e-05	0.000367	CcSEcCtD
Nilotinib—Loss of consciousness—Dexamethasone—multiple sclerosis	9.72e-05	0.000367	CcSEcCtD
Nilotinib—Loss of consciousness—Betamethasone—multiple sclerosis	9.72e-05	0.000367	CcSEcCtD
Nilotinib—Epistaxis—Methotrexate—multiple sclerosis	9.72e-05	0.000367	CcSEcCtD
Nilotinib—Hypersensitivity—Mitoxantrone—multiple sclerosis	9.72e-05	0.000367	CcSEcCtD
Nilotinib—Paraesthesia—Prednisolone—multiple sclerosis	9.72e-05	0.000367	CcSEcCtD
Nilotinib—Tachycardia—Triamcinolone—multiple sclerosis	9.71e-05	0.000366	CcSEcCtD
Nilotinib—Mental disorder—Prednisone—multiple sclerosis	9.7e-05	0.000366	CcSEcCtD
Nilotinib—Nausea—Azathioprine—multiple sclerosis	9.69e-05	0.000366	CcSEcCtD
Nilotinib—Tachycardia—Methylprednisolone—multiple sclerosis	9.69e-05	0.000366	CcSEcCtD
Nilotinib—Skin disorder—Methylprednisolone—multiple sclerosis	9.65e-05	0.000364	CcSEcCtD
Nilotinib—Malnutrition—Prednisone—multiple sclerosis	9.64e-05	0.000363	CcSEcCtD
Nilotinib—Erythema—Prednisone—multiple sclerosis	9.64e-05	0.000363	CcSEcCtD
Nilotinib—Hyperhidrosis—Triamcinolone—multiple sclerosis	9.62e-05	0.000363	CcSEcCtD
Nilotinib—Hyperhidrosis—Methylprednisolone—multiple sclerosis	9.6e-05	0.000362	CcSEcCtD
Nilotinib—Hypertension—Dexamethasone—multiple sclerosis	9.55e-05	0.00036	CcSEcCtD
Nilotinib—Hypertension—Betamethasone—multiple sclerosis	9.55e-05	0.00036	CcSEcCtD
Nilotinib—Asthenia—Mitoxantrone—multiple sclerosis	9.46e-05	0.000357	CcSEcCtD
Nilotinib—Myalgia—Dexamethasone—multiple sclerosis	9.42e-05	0.000355	CcSEcCtD
Nilotinib—Myalgia—Betamethasone—multiple sclerosis	9.42e-05	0.000355	CcSEcCtD
Nilotinib—Anxiety—Dexamethasone—multiple sclerosis	9.39e-05	0.000354	CcSEcCtD
Nilotinib—Anxiety—Betamethasone—multiple sclerosis	9.39e-05	0.000354	CcSEcCtD
Nilotinib—Discomfort—Dexamethasone—multiple sclerosis	9.31e-05	0.000351	CcSEcCtD
Nilotinib—Discomfort—Betamethasone—multiple sclerosis	9.31e-05	0.000351	CcSEcCtD
Nilotinib—Haemoglobin—Methotrexate—multiple sclerosis	9.3e-05	0.000351	CcSEcCtD
Nilotinib—Hypotension—Methylprednisolone—multiple sclerosis	9.28e-05	0.00035	CcSEcCtD
Nilotinib—Pain—Prednisolone—multiple sclerosis	9.25e-05	0.000349	CcSEcCtD
Nilotinib—Haemorrhage—Methotrexate—multiple sclerosis	9.25e-05	0.000349	CcSEcCtD
Nilotinib—Hepatitis—Methotrexate—multiple sclerosis	9.25e-05	0.000349	CcSEcCtD
Nilotinib—Pharyngitis—Methotrexate—multiple sclerosis	9.18e-05	0.000346	CcSEcCtD
Nilotinib—Urinary tract disorder—Methotrexate—multiple sclerosis	9.14e-05	0.000345	CcSEcCtD
Nilotinib—Vision blurred—Prednisone—multiple sclerosis	9.08e-05	0.000343	CcSEcCtD
Nilotinib—Urethral disorder—Methotrexate—multiple sclerosis	9.07e-05	0.000342	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	9.07e-05	0.000342	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	9.05e-05	0.000341	CcSEcCtD
Nilotinib—Oedema—Dexamethasone—multiple sclerosis	9.03e-05	0.000341	CcSEcCtD
Nilotinib—Oedema—Betamethasone—multiple sclerosis	9.03e-05	0.000341	CcSEcCtD
Nilotinib—Diarrhoea—Mitoxantrone—multiple sclerosis	9.03e-05	0.00034	CcSEcCtD
Nilotinib—Insomnia—Triamcinolone—multiple sclerosis	9e-05	0.00034	CcSEcCtD
Nilotinib—Insomnia—Methylprednisolone—multiple sclerosis	8.98e-05	0.000339	CcSEcCtD
Nilotinib—Infection—Betamethasone—multiple sclerosis	8.97e-05	0.000338	CcSEcCtD
Nilotinib—Infection—Dexamethasone—multiple sclerosis	8.97e-05	0.000338	CcSEcCtD
Nilotinib—Ill-defined disorder—Prednisone—multiple sclerosis	8.94e-05	0.000337	CcSEcCtD
Nilotinib—Paraesthesia—Triamcinolone—multiple sclerosis	8.94e-05	0.000337	CcSEcCtD
Nilotinib—Feeling abnormal—Prednisolone—multiple sclerosis	8.92e-05	0.000336	CcSEcCtD
Nilotinib—Paraesthesia—Methylprednisolone—multiple sclerosis	8.92e-05	0.000336	CcSEcCtD
Nilotinib—Visual impairment—Methotrexate—multiple sclerosis	8.91e-05	0.000336	CcSEcCtD
Nilotinib—Anaemia—Prednisone—multiple sclerosis	8.91e-05	0.000336	CcSEcCtD
Nilotinib—Shock—Dexamethasone—multiple sclerosis	8.88e-05	0.000335	CcSEcCtD
Nilotinib—Shock—Betamethasone—multiple sclerosis	8.88e-05	0.000335	CcSEcCtD
Nilotinib—Dyspnoea—Triamcinolone—multiple sclerosis	8.87e-05	0.000335	CcSEcCtD
Nilotinib—Nervous system disorder—Dexamethasone—multiple sclerosis	8.86e-05	0.000334	CcSEcCtD
Nilotinib—Nervous system disorder—Betamethasone—multiple sclerosis	8.86e-05	0.000334	CcSEcCtD
Nilotinib—Thrombocytopenia—Dexamethasone—multiple sclerosis	8.84e-05	0.000334	CcSEcCtD
Nilotinib—Thrombocytopenia—Betamethasone—multiple sclerosis	8.84e-05	0.000334	CcSEcCtD
Nilotinib—Tachycardia—Dexamethasone—multiple sclerosis	8.81e-05	0.000332	CcSEcCtD
Nilotinib—Tachycardia—Betamethasone—multiple sclerosis	8.81e-05	0.000332	CcSEcCtD
Nilotinib—Dyspepsia—Triamcinolone—multiple sclerosis	8.76e-05	0.00033	CcSEcCtD
Nilotinib—Erythema multiforme—Methotrexate—multiple sclerosis	8.75e-05	0.00033	CcSEcCtD
Nilotinib—Dyspepsia—Methylprednisolone—multiple sclerosis	8.74e-05	0.00033	CcSEcCtD
Nilotinib—Hyperhidrosis—Dexamethasone—multiple sclerosis	8.73e-05	0.000329	CcSEcCtD
Nilotinib—Hyperhidrosis—Betamethasone—multiple sclerosis	8.73e-05	0.000329	CcSEcCtD
Nilotinib—Malaise—Prednisone—multiple sclerosis	8.69e-05	0.000328	CcSEcCtD
Nilotinib—Vertigo—Prednisone—multiple sclerosis	8.66e-05	0.000327	CcSEcCtD
Nilotinib—Eye disorder—Methotrexate—multiple sclerosis	8.64e-05	0.000326	CcSEcCtD
Nilotinib—Syncope—Prednisone—multiple sclerosis	8.64e-05	0.000326	CcSEcCtD
Nilotinib—Tinnitus—Methotrexate—multiple sclerosis	8.62e-05	0.000325	CcSEcCtD
Nilotinib—Anorexia—Betamethasone—multiple sclerosis	8.61e-05	0.000325	CcSEcCtD
Nilotinib—Anorexia—Dexamethasone—multiple sclerosis	8.61e-05	0.000325	CcSEcCtD
Nilotinib—Urticaria—Prednisolone—multiple sclerosis	8.6e-05	0.000324	CcSEcCtD
Nilotinib—Cardiac disorder—Methotrexate—multiple sclerosis	8.59e-05	0.000324	CcSEcCtD
Nilotinib—Fatigue—Triamcinolone—multiple sclerosis	8.58e-05	0.000324	CcSEcCtD
Nilotinib—Fatigue—Methylprednisolone—multiple sclerosis	8.56e-05	0.000323	CcSEcCtD
Nilotinib—Pain—Triamcinolone—multiple sclerosis	8.51e-05	0.000321	CcSEcCtD
Nilotinib—Loss of consciousness—Prednisone—multiple sclerosis	8.47e-05	0.000319	CcSEcCtD
Nilotinib—Hypotension—Dexamethasone—multiple sclerosis	8.44e-05	0.000318	CcSEcCtD
Nilotinib—Hypotension—Betamethasone—multiple sclerosis	8.44e-05	0.000318	CcSEcCtD
Nilotinib—Angiopathy—Methotrexate—multiple sclerosis	8.39e-05	0.000317	CcSEcCtD
Nilotinib—Vomiting—Mitoxantrone—multiple sclerosis	8.39e-05	0.000316	CcSEcCtD
Nilotinib—Immune system disorder—Methotrexate—multiple sclerosis	8.36e-05	0.000315	CcSEcCtD
Nilotinib—Mediastinal disorder—Methotrexate—multiple sclerosis	8.34e-05	0.000315	CcSEcCtD
Nilotinib—Hypertension—Prednisone—multiple sclerosis	8.32e-05	0.000314	CcSEcCtD
Nilotinib—Rash—Mitoxantrone—multiple sclerosis	8.32e-05	0.000314	CcSEcCtD
Nilotinib—Dermatitis—Mitoxantrone—multiple sclerosis	8.31e-05	0.000313	CcSEcCtD
Nilotinib—Chills—Methotrexate—multiple sclerosis	8.3e-05	0.000313	CcSEcCtD
Nilotinib—Headache—Mitoxantrone—multiple sclerosis	8.26e-05	0.000312	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	8.23e-05	0.00031	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	8.23e-05	0.00031	CcSEcCtD
Nilotinib—Arthralgia—Prednisone—multiple sclerosis	8.2e-05	0.000309	CcSEcCtD
Nilotinib—Myalgia—Prednisone—multiple sclerosis	8.2e-05	0.000309	CcSEcCtD
Nilotinib—Feeling abnormal—Triamcinolone—multiple sclerosis	8.2e-05	0.000309	CcSEcCtD
Nilotinib—Feeling abnormal—Methylprednisolone—multiple sclerosis	8.18e-05	0.000309	CcSEcCtD
Nilotinib—Anxiety—Prednisone—multiple sclerosis	8.17e-05	0.000308	CcSEcCtD
Nilotinib—Alopecia—Methotrexate—multiple sclerosis	8.17e-05	0.000308	CcSEcCtD
Nilotinib—Insomnia—Dexamethasone—multiple sclerosis	8.17e-05	0.000308	CcSEcCtD
Nilotinib—Insomnia—Betamethasone—multiple sclerosis	8.17e-05	0.000308	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	8.15e-05	0.000307	CcSEcCtD
Nilotinib—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	8.12e-05	0.000306	CcSEcCtD
Nilotinib—Paraesthesia—Dexamethasone—multiple sclerosis	8.11e-05	0.000306	CcSEcCtD
Nilotinib—Paraesthesia—Betamethasone—multiple sclerosis	8.11e-05	0.000306	CcSEcCtD
Nilotinib—Discomfort—Prednisone—multiple sclerosis	8.11e-05	0.000306	CcSEcCtD
Nilotinib—Mental disorder—Methotrexate—multiple sclerosis	8.1e-05	0.000306	CcSEcCtD
Nilotinib—Erythema—Methotrexate—multiple sclerosis	8.05e-05	0.000304	CcSEcCtD
Nilotinib—Malnutrition—Methotrexate—multiple sclerosis	8.05e-05	0.000304	CcSEcCtD
Nilotinib—Hypersensitivity—Prednisolone—multiple sclerosis	7.97e-05	0.000301	CcSEcCtD
Nilotinib—Dyspepsia—Betamethasone—multiple sclerosis	7.95e-05	0.0003	CcSEcCtD
Nilotinib—Dyspepsia—Dexamethasone—multiple sclerosis	7.95e-05	0.0003	CcSEcCtD
Nilotinib—ABCB1—brain—multiple sclerosis	7.92e-05	0.000602	CbGeAlD
Nilotinib—Urticaria—Triamcinolone—multiple sclerosis	7.91e-05	0.000298	CcSEcCtD
Nilotinib—Urticaria—Methylprednisolone—multiple sclerosis	7.89e-05	0.000298	CcSEcCtD
Nilotinib—Dysgeusia—Methotrexate—multiple sclerosis	7.89e-05	0.000297	CcSEcCtD
Nilotinib—Body temperature increased—Triamcinolone—multiple sclerosis	7.87e-05	0.000297	CcSEcCtD
Nilotinib—Oedema—Prednisone—multiple sclerosis	7.86e-05	0.000297	CcSEcCtD
Nilotinib—Abdominal pain—Methylprednisolone—multiple sclerosis	7.85e-05	0.000296	CcSEcCtD
Nilotinib—Decreased appetite—Dexamethasone—multiple sclerosis	7.85e-05	0.000296	CcSEcCtD
Nilotinib—Decreased appetite—Betamethasone—multiple sclerosis	7.85e-05	0.000296	CcSEcCtD
Nilotinib—Nausea—Mitoxantrone—multiple sclerosis	7.84e-05	0.000296	CcSEcCtD
Nilotinib—Infection—Prednisone—multiple sclerosis	7.81e-05	0.000295	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	7.8e-05	0.000294	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Betamethasone—multiple sclerosis	7.8e-05	0.000294	CcSEcCtD
Nilotinib—Back pain—Methotrexate—multiple sclerosis	7.79e-05	0.000294	CcSEcCtD
Nilotinib—Fatigue—Dexamethasone—multiple sclerosis	7.79e-05	0.000294	CcSEcCtD
Nilotinib—Fatigue—Betamethasone—multiple sclerosis	7.79e-05	0.000294	CcSEcCtD
Nilotinib—Shock—Prednisone—multiple sclerosis	7.74e-05	0.000292	CcSEcCtD
Nilotinib—Pain—Dexamethasone—multiple sclerosis	7.72e-05	0.000291	CcSEcCtD
Nilotinib—Pain—Betamethasone—multiple sclerosis	7.72e-05	0.000291	CcSEcCtD
Nilotinib—Nervous system disorder—Prednisone—multiple sclerosis	7.71e-05	0.000291	CcSEcCtD
Nilotinib—Tachycardia—Prednisone—multiple sclerosis	7.68e-05	0.00029	CcSEcCtD
Nilotinib—Skin disorder—Prednisone—multiple sclerosis	7.64e-05	0.000288	CcSEcCtD
Nilotinib—Hyperhidrosis—Prednisone—multiple sclerosis	7.6e-05	0.000287	CcSEcCtD
Nilotinib—Vision blurred—Methotrexate—multiple sclerosis	7.59e-05	0.000286	CcSEcCtD
Nilotinib—Anorexia—Prednisone—multiple sclerosis	7.5e-05	0.000283	CcSEcCtD
Nilotinib—Ill-defined disorder—Methotrexate—multiple sclerosis	7.47e-05	0.000282	CcSEcCtD
Nilotinib—Anaemia—Methotrexate—multiple sclerosis	7.44e-05	0.000281	CcSEcCtD
Nilotinib—Feeling abnormal—Dexamethasone—multiple sclerosis	7.44e-05	0.000281	CcSEcCtD
Nilotinib—Feeling abnormal—Betamethasone—multiple sclerosis	7.44e-05	0.000281	CcSEcCtD
Nilotinib—Gastrointestinal pain—Dexamethasone—multiple sclerosis	7.38e-05	0.000279	CcSEcCtD
Nilotinib—Gastrointestinal pain—Betamethasone—multiple sclerosis	7.38e-05	0.000279	CcSEcCtD
Nilotinib—Hypersensitivity—Triamcinolone—multiple sclerosis	7.33e-05	0.000277	CcSEcCtD
Nilotinib—Hypersensitivity—Methylprednisolone—multiple sclerosis	7.32e-05	0.000276	CcSEcCtD
Nilotinib—Malaise—Methotrexate—multiple sclerosis	7.26e-05	0.000274	CcSEcCtD
Nilotinib—Vertigo—Methotrexate—multiple sclerosis	7.23e-05	0.000273	CcSEcCtD
Nilotinib—Leukopenia—Methotrexate—multiple sclerosis	7.21e-05	0.000272	CcSEcCtD
Nilotinib—Urticaria—Dexamethasone—multiple sclerosis	7.17e-05	0.000271	CcSEcCtD
Nilotinib—Urticaria—Betamethasone—multiple sclerosis	7.17e-05	0.000271	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Prednisone—multiple sclerosis	7.16e-05	0.00027	CcSEcCtD
Nilotinib—Dizziness—Prednisolone—multiple sclerosis	7.16e-05	0.00027	CcSEcCtD
Nilotinib—Asthenia—Triamcinolone—multiple sclerosis	7.14e-05	0.000269	CcSEcCtD
Nilotinib—Abdominal pain—Dexamethasone—multiple sclerosis	7.14e-05	0.000269	CcSEcCtD
Nilotinib—Abdominal pain—Betamethasone—multiple sclerosis	7.14e-05	0.000269	CcSEcCtD
Nilotinib—Body temperature increased—Betamethasone—multiple sclerosis	7.14e-05	0.000269	CcSEcCtD
Nilotinib—Body temperature increased—Dexamethasone—multiple sclerosis	7.14e-05	0.000269	CcSEcCtD
Nilotinib—Asthenia—Methylprednisolone—multiple sclerosis	7.12e-05	0.000269	CcSEcCtD
Nilotinib—Insomnia—Prednisone—multiple sclerosis	7.11e-05	0.000268	CcSEcCtD
Nilotinib—Paraesthesia—Prednisone—multiple sclerosis	7.06e-05	0.000266	CcSEcCtD
Nilotinib—Pruritus—Triamcinolone—multiple sclerosis	7.04e-05	0.000266	CcSEcCtD
Nilotinib—Cough—Methotrexate—multiple sclerosis	7.03e-05	0.000265	CcSEcCtD
Nilotinib—Pruritus—Methylprednisolone—multiple sclerosis	7.03e-05	0.000265	CcSEcCtD
Nilotinib—Dyspepsia—Prednisone—multiple sclerosis	6.92e-05	0.000261	CcSEcCtD
Nilotinib—Arthralgia—Methotrexate—multiple sclerosis	6.86e-05	0.000259	CcSEcCtD
Nilotinib—Chest pain—Methotrexate—multiple sclerosis	6.86e-05	0.000259	CcSEcCtD
Nilotinib—Myalgia—Methotrexate—multiple sclerosis	6.86e-05	0.000259	CcSEcCtD
Nilotinib—Decreased appetite—Prednisone—multiple sclerosis	6.84e-05	0.000258	CcSEcCtD
Nilotinib—Rash—Prednisolone—multiple sclerosis	6.82e-05	0.000257	CcSEcCtD
Nilotinib—Dermatitis—Prednisolone—multiple sclerosis	6.82e-05	0.000257	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	6.81e-05	0.000257	CcSEcCtD
Nilotinib—Diarrhoea—Methylprednisolone—multiple sclerosis	6.79e-05	0.000256	CcSEcCtD
Nilotinib—Fatigue—Prednisone—multiple sclerosis	6.78e-05	0.000256	CcSEcCtD
Nilotinib—Headache—Prednisolone—multiple sclerosis	6.78e-05	0.000256	CcSEcCtD
Nilotinib—Discomfort—Methotrexate—multiple sclerosis	6.77e-05	0.000256	CcSEcCtD
Nilotinib—Constipation—Prednisone—multiple sclerosis	6.72e-05	0.000254	CcSEcCtD
Nilotinib—Confusional state—Methotrexate—multiple sclerosis	6.63e-05	0.00025	CcSEcCtD
Nilotinib—Dizziness—Triamcinolone—multiple sclerosis	6.58e-05	0.000248	CcSEcCtD
Nilotinib—Dizziness—Methylprednisolone—multiple sclerosis	6.57e-05	0.000248	CcSEcCtD
Nilotinib—Infection—Methotrexate—multiple sclerosis	6.53e-05	0.000246	CcSEcCtD
Nilotinib—Feeling abnormal—Prednisone—multiple sclerosis	6.48e-05	0.000244	CcSEcCtD
Nilotinib—Asthenia—Dexamethasone—multiple sclerosis	6.48e-05	0.000244	CcSEcCtD
Nilotinib—Asthenia—Betamethasone—multiple sclerosis	6.48e-05	0.000244	CcSEcCtD
Nilotinib—Nervous system disorder—Methotrexate—multiple sclerosis	6.45e-05	0.000243	CcSEcCtD
Nilotinib—Thrombocytopenia—Methotrexate—multiple sclerosis	6.43e-05	0.000243	CcSEcCtD
Nilotinib—Gastrointestinal pain—Prednisone—multiple sclerosis	6.43e-05	0.000243	CcSEcCtD
Nilotinib—Nausea—Prednisolone—multiple sclerosis	6.43e-05	0.000242	CcSEcCtD
Nilotinib—Pruritus—Dexamethasone—multiple sclerosis	6.39e-05	0.000241	CcSEcCtD
Nilotinib—Pruritus—Betamethasone—multiple sclerosis	6.39e-05	0.000241	CcSEcCtD
Nilotinib—Skin disorder—Methotrexate—multiple sclerosis	6.38e-05	0.000241	CcSEcCtD
Nilotinib—Hyperhidrosis—Methotrexate—multiple sclerosis	6.35e-05	0.00024	CcSEcCtD
Nilotinib—Vomiting—Triamcinolone—multiple sclerosis	6.33e-05	0.000239	CcSEcCtD
Nilotinib—Vomiting—Methylprednisolone—multiple sclerosis	6.31e-05	0.000238	CcSEcCtD
Nilotinib—Rash—Triamcinolone—multiple sclerosis	6.27e-05	0.000237	CcSEcCtD
Nilotinib—Dermatitis—Triamcinolone—multiple sclerosis	6.27e-05	0.000236	CcSEcCtD
Nilotinib—Anorexia—Methotrexate—multiple sclerosis	6.26e-05	0.000236	CcSEcCtD
Nilotinib—Rash—Methylprednisolone—multiple sclerosis	6.26e-05	0.000236	CcSEcCtD
Nilotinib—Dermatitis—Methylprednisolone—multiple sclerosis	6.26e-05	0.000236	CcSEcCtD
Nilotinib—Urticaria—Prednisone—multiple sclerosis	6.25e-05	0.000236	CcSEcCtD
Nilotinib—Headache—Triamcinolone—multiple sclerosis	6.23e-05	0.000235	CcSEcCtD
Nilotinib—Headache—Methylprednisolone—multiple sclerosis	6.22e-05	0.000235	CcSEcCtD
Nilotinib—Abdominal pain—Prednisone—multiple sclerosis	6.22e-05	0.000235	CcSEcCtD
Nilotinib—Body temperature increased—Prednisone—multiple sclerosis	6.22e-05	0.000235	CcSEcCtD
Nilotinib—Diarrhoea—Dexamethasone—multiple sclerosis	6.18e-05	0.000233	CcSEcCtD
Nilotinib—Diarrhoea—Betamethasone—multiple sclerosis	6.18e-05	0.000233	CcSEcCtD
Nilotinib—Hypotension—Methotrexate—multiple sclerosis	6.14e-05	0.000232	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	5.99e-05	0.000226	CcSEcCtD
Nilotinib—Dizziness—Betamethasone—multiple sclerosis	5.97e-05	0.000225	CcSEcCtD
Nilotinib—Dizziness—Dexamethasone—multiple sclerosis	5.97e-05	0.000225	CcSEcCtD
Nilotinib—Insomnia—Methotrexate—multiple sclerosis	5.94e-05	0.000224	CcSEcCtD
Nilotinib—Nausea—Triamcinolone—multiple sclerosis	5.91e-05	0.000223	CcSEcCtD
Nilotinib—Paraesthesia—Methotrexate—multiple sclerosis	5.9e-05	0.000223	CcSEcCtD
Nilotinib—Nausea—Methylprednisolone—multiple sclerosis	5.9e-05	0.000223	CcSEcCtD
Nilotinib—Dyspnoea—Methotrexate—multiple sclerosis	5.86e-05	0.000221	CcSEcCtD
Nilotinib—Hypersensitivity—Prednisone—multiple sclerosis	5.79e-05	0.000219	CcSEcCtD
Nilotinib—Dyspepsia—Methotrexate—multiple sclerosis	5.79e-05	0.000218	CcSEcCtD
Nilotinib—Vomiting—Betamethasone—multiple sclerosis	5.74e-05	0.000217	CcSEcCtD
Nilotinib—Vomiting—Dexamethasone—multiple sclerosis	5.74e-05	0.000217	CcSEcCtD
Nilotinib—Decreased appetite—Methotrexate—multiple sclerosis	5.71e-05	0.000216	CcSEcCtD
Nilotinib—Rash—Dexamethasone—multiple sclerosis	5.69e-05	0.000215	CcSEcCtD
Nilotinib—Rash—Betamethasone—multiple sclerosis	5.69e-05	0.000215	CcSEcCtD
Nilotinib—Dermatitis—Dexamethasone—multiple sclerosis	5.69e-05	0.000215	CcSEcCtD
Nilotinib—Dermatitis—Betamethasone—multiple sclerosis	5.69e-05	0.000215	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Methotrexate—multiple sclerosis	5.67e-05	0.000214	CcSEcCtD
Nilotinib—Fatigue—Methotrexate—multiple sclerosis	5.67e-05	0.000214	CcSEcCtD
Nilotinib—Headache—Dexamethasone—multiple sclerosis	5.66e-05	0.000213	CcSEcCtD
Nilotinib—Headache—Betamethasone—multiple sclerosis	5.66e-05	0.000213	CcSEcCtD
Nilotinib—Asthenia—Prednisone—multiple sclerosis	5.64e-05	0.000213	CcSEcCtD
Nilotinib—Pain—Methotrexate—multiple sclerosis	5.62e-05	0.000212	CcSEcCtD
Nilotinib—Pruritus—Prednisone—multiple sclerosis	5.56e-05	0.00021	CcSEcCtD
Nilotinib—Feeling abnormal—Methotrexate—multiple sclerosis	5.42e-05	0.000204	CcSEcCtD
Nilotinib—Diarrhoea—Prednisone—multiple sclerosis	5.38e-05	0.000203	CcSEcCtD
Nilotinib—Gastrointestinal pain—Methotrexate—multiple sclerosis	5.37e-05	0.000203	CcSEcCtD
Nilotinib—Nausea—Betamethasone—multiple sclerosis	5.36e-05	0.000202	CcSEcCtD
Nilotinib—Nausea—Dexamethasone—multiple sclerosis	5.36e-05	0.000202	CcSEcCtD
Nilotinib—Urticaria—Methotrexate—multiple sclerosis	5.22e-05	0.000197	CcSEcCtD
Nilotinib—Dizziness—Prednisone—multiple sclerosis	5.2e-05	0.000196	CcSEcCtD
Nilotinib—Abdominal pain—Methotrexate—multiple sclerosis	5.2e-05	0.000196	CcSEcCtD
Nilotinib—Body temperature increased—Methotrexate—multiple sclerosis	5.2e-05	0.000196	CcSEcCtD
Nilotinib—Vomiting—Prednisone—multiple sclerosis	5e-05	0.000189	CcSEcCtD
Nilotinib—Rash—Prednisone—multiple sclerosis	4.96e-05	0.000187	CcSEcCtD
Nilotinib—Dermatitis—Prednisone—multiple sclerosis	4.95e-05	0.000187	CcSEcCtD
Nilotinib—Headache—Prednisone—multiple sclerosis	4.93e-05	0.000186	CcSEcCtD
Nilotinib—Hypersensitivity—Methotrexate—multiple sclerosis	4.84e-05	0.000183	CcSEcCtD
Nilotinib—Asthenia—Methotrexate—multiple sclerosis	4.72e-05	0.000178	CcSEcCtD
Nilotinib—Nausea—Prednisone—multiple sclerosis	4.67e-05	0.000176	CcSEcCtD
Nilotinib—Pruritus—Methotrexate—multiple sclerosis	4.65e-05	0.000175	CcSEcCtD
Nilotinib—Diarrhoea—Methotrexate—multiple sclerosis	4.5e-05	0.00017	CcSEcCtD
Nilotinib—Dizziness—Methotrexate—multiple sclerosis	4.35e-05	0.000164	CcSEcCtD
Nilotinib—Vomiting—Methotrexate—multiple sclerosis	4.18e-05	0.000158	CcSEcCtD
Nilotinib—Rash—Methotrexate—multiple sclerosis	4.14e-05	0.000156	CcSEcCtD
Nilotinib—Dermatitis—Methotrexate—multiple sclerosis	4.14e-05	0.000156	CcSEcCtD
Nilotinib—Headache—Methotrexate—multiple sclerosis	4.12e-05	0.000155	CcSEcCtD
Nilotinib—Nausea—Methotrexate—multiple sclerosis	3.9e-05	0.000147	CcSEcCtD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	5.25e-06	2.03e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—APOE—multiple sclerosis	5.23e-06	2.02e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—POMC—multiple sclerosis	5.22e-06	2.01e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—SPP1—multiple sclerosis	5.21e-06	2.01e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IFNG—multiple sclerosis	5.21e-06	2.01e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—IL6—multiple sclerosis	5.19e-06	2e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CCR5—multiple sclerosis	5.18e-06	2e-05	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—IL6—multiple sclerosis	5.18e-06	2e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—APOE—multiple sclerosis	5.16e-06	1.99e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—TYK2—multiple sclerosis	5.16e-06	1.99e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—IL1B—multiple sclerosis	5.16e-06	1.99e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—CD4—multiple sclerosis	5.16e-06	1.99e-05	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—IL6—multiple sclerosis	5.16e-06	1.99e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—CCL2—multiple sclerosis	5.15e-06	1.99e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—IL2—multiple sclerosis	5.14e-06	1.98e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—TYK2—multiple sclerosis	5.14e-06	1.98e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IL2RA—multiple sclerosis	5.11e-06	1.97e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—CCL2—multiple sclerosis	5.1e-06	1.97e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—IFNG—multiple sclerosis	5.1e-06	1.97e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GPC5—multiple sclerosis	5.1e-06	1.97e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IFNG—multiple sclerosis	5.08e-06	1.96e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CCR5—multiple sclerosis	5.07e-06	1.96e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—STAT3—multiple sclerosis	5.07e-06	1.96e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—CD4—multiple sclerosis	5.03e-06	1.94e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IL2RA—multiple sclerosis	5e-06	1.93e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CD80—multiple sclerosis	5e-06	1.93e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	4.97e-06	1.92e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—SPP1—multiple sclerosis	4.94e-06	1.91e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—CD4—multiple sclerosis	4.93e-06	1.9e-05	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—IL6—multiple sclerosis	4.91e-06	1.9e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CD4—multiple sclerosis	4.9e-06	1.89e-05	CbGpPWpGaD
Nilotinib—HCK—Immune System—IL6—multiple sclerosis	4.9e-06	1.89e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—IL2—multiple sclerosis	4.89e-06	1.89e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—CD80—multiple sclerosis	4.88e-06	1.89e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—MAPK1—multiple sclerosis	4.88e-06	1.88e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IFNG—multiple sclerosis	4.84e-06	1.87e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CCR5—multiple sclerosis	4.81e-06	1.86e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	4.78e-06	1.85e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—POMC—multiple sclerosis	4.75e-06	1.83e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL2RA—multiple sclerosis	4.74e-06	1.83e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CD80—multiple sclerosis	4.73e-06	1.83e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—APOE—multiple sclerosis	4.71e-06	1.82e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CD86—multiple sclerosis	4.69e-06	1.81e-05	CbGpPWpGaD
Nilotinib—MAPK11—Gene Expression—MYC—multiple sclerosis	4.68e-06	1.81e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TYK2—multiple sclerosis	4.68e-06	1.81e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—IL6—multiple sclerosis	4.67e-06	1.8e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CD4—multiple sclerosis	4.67e-06	1.8e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IL1B—multiple sclerosis	4.65e-06	1.79e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—CD4—multiple sclerosis	4.65e-06	1.79e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CCL2—multiple sclerosis	4.65e-06	1.79e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—IL2—multiple sclerosis	4.65e-06	1.79e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TYK2—multiple sclerosis	4.63e-06	1.79e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—STAT3—multiple sclerosis	4.63e-06	1.79e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IL2—multiple sclerosis	4.63e-06	1.79e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—MMP9—multiple sclerosis	4.62e-06	1.79e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CCL5—multiple sclerosis	4.61e-06	1.78e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—APOE—multiple sclerosis	4.61e-06	1.78e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—MAPK1—multiple sclerosis	4.61e-06	1.78e-05	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—IL6—multiple sclerosis	4.57e-06	1.77e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—STAT3—multiple sclerosis	4.57e-06	1.76e-05	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—IL6—multiple sclerosis	4.55e-06	1.76e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL1B—multiple sclerosis	4.55e-06	1.76e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL2—multiple sclerosis	4.53e-06	1.75e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL1B—multiple sclerosis	4.53e-06	1.75e-05	CbGpPWpGaD
Nilotinib—HCK—Disease—IL6—multiple sclerosis	4.53e-06	1.75e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—BCHE—multiple sclerosis	4.52e-06	1.75e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL2—multiple sclerosis	4.51e-06	1.74e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—POMC—multiple sclerosis	4.49e-06	1.73e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—TYK2—multiple sclerosis	4.47e-06	1.72e-05	CbGpPWpGaD
Nilotinib—BLK—Immune System—IL6—multiple sclerosis	4.44e-06	1.71e-05	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—IL6—multiple sclerosis	4.44e-06	1.71e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—POMC—multiple sclerosis	4.44e-06	1.71e-05	CbGpPWpGaD
Nilotinib—FGR—Immune System—IL6—multiple sclerosis	4.43e-06	1.71e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CCL2—multiple sclerosis	4.4e-06	1.7e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—MMP9—multiple sclerosis	4.4e-06	1.7e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—APOE—multiple sclerosis	4.38e-06	1.69e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—APOE—multiple sclerosis	4.37e-06	1.69e-05	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—IL6—multiple sclerosis	4.34e-06	1.67e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—STAT3—multiple sclerosis	4.32e-06	1.67e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL1B—multiple sclerosis	4.31e-06	1.67e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—MYC—multiple sclerosis	4.31e-06	1.66e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL2—multiple sclerosis	4.3e-06	1.66e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—TGFB1—multiple sclerosis	4.3e-06	1.66e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—SPP1—multiple sclerosis	4.27e-06	1.65e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	4.27e-06	1.65e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CD80—multiple sclerosis	4.26e-06	1.65e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—RRM1—multiple sclerosis	4.22e-06	1.63e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TYK2—multiple sclerosis	4.22e-06	1.63e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—STAT3—multiple sclerosis	4.22e-06	1.63e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—MAPK1—multiple sclerosis	4.21e-06	1.63e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—IFNG—multiple sclerosis	4.18e-06	1.61e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CD80—multiple sclerosis	4.17e-06	1.61e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CCR5—multiple sclerosis	4.16e-06	1.6e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—MAPK1—multiple sclerosis	4.15e-06	1.6e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—TYK2—multiple sclerosis	4.12e-06	1.59e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—STAT3—multiple sclerosis	4.11e-06	1.59e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL2RA—multiple sclerosis	4.1e-06	1.58e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—POMC—multiple sclerosis	4.05e-06	1.56e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—ALB—multiple sclerosis	4.05e-06	1.56e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—CD4—multiple sclerosis	4.04e-06	1.56e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TYK2—multiple sclerosis	3.99e-06	1.54e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—STAT3—multiple sclerosis	3.99e-06	1.54e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—POMC—multiple sclerosis	3.96e-06	1.53e-05	CbGpPWpGaD
Nilotinib—ABCB1—Transmembrane transport of small molecules—ALB—multiple sclerosis	3.96e-06	1.53e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CCL2—multiple sclerosis	3.96e-06	1.53e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CD80—multiple sclerosis	3.96e-06	1.53e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—BCHE—multiple sclerosis	3.94e-06	1.52e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—MAPK1—multiple sclerosis	3.93e-06	1.52e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—MYC—multiple sclerosis	3.92e-06	1.51e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—TGFB1—multiple sclerosis	3.91e-06	1.51e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—STAT3—multiple sclerosis	3.91e-06	1.51e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—STAT3—multiple sclerosis	3.9e-06	1.5e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—IL2—multiple sclerosis	3.89e-06	1.5e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	3.89e-06	1.5e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CCL2—multiple sclerosis	3.88e-06	1.5e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—IL2—multiple sclerosis	3.86e-06	1.49e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—MAPK1—multiple sclerosis	3.83e-06	1.48e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—MYC—multiple sclerosis	3.82e-06	1.47e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—STAT3—multiple sclerosis	3.81e-06	1.47e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—TGFB1—multiple sclerosis	3.81e-06	1.47e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—STAT3—multiple sclerosis	3.8e-06	1.47e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—APOE—multiple sclerosis	3.78e-06	1.46e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—POMC—multiple sclerosis	3.76e-06	1.45e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—POMC—multiple sclerosis	3.76e-06	1.45e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—IL6—multiple sclerosis	3.75e-06	1.45e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—MAPK1—multiple sclerosis	3.74e-06	1.44e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL1B—multiple sclerosis	3.73e-06	1.44e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—CD4—multiple sclerosis	3.73e-06	1.44e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL2—multiple sclerosis	3.72e-06	1.43e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—BCHE—multiple sclerosis	3.71e-06	1.43e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—MYC—multiple sclerosis	3.71e-06	1.43e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—TGFB1—multiple sclerosis	3.7e-06	1.43e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—MMP9—multiple sclerosis	3.68e-06	1.42e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—BCHE—multiple sclerosis	3.68e-06	1.42e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CCL2—multiple sclerosis	3.68e-06	1.42e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—MMP9—multiple sclerosis	3.65e-06	1.41e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—MYC—multiple sclerosis	3.63e-06	1.4e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—MAPK1—multiple sclerosis	3.63e-06	1.4e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—TGFB1—multiple sclerosis	3.62e-06	1.4e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—STAT3—multiple sclerosis	3.62e-06	1.4e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TYK2—multiple sclerosis	3.6e-06	1.39e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—STAT3—multiple sclerosis	3.6e-06	1.39e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—MAPK1—multiple sclerosis	3.55e-06	1.37e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—MAPK1—multiple sclerosis	3.54e-06	1.37e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—IL6—multiple sclerosis	3.54e-06	1.37e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TYK2—multiple sclerosis	3.52e-06	1.36e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IL2—multiple sclerosis	3.51e-06	1.36e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—MAPK1—multiple sclerosis	3.47e-06	1.34e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—MAPK1—multiple sclerosis	3.45e-06	1.33e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—ALB—multiple sclerosis	3.43e-06	1.32e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CD80—multiple sclerosis	3.42e-06	1.32e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—MYC—multiple sclerosis	3.34e-06	1.29e-05	CbGpPWpGaD
Nilotinib—MAPK14—Gene Expression—MYC—multiple sclerosis	3.34e-06	1.29e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TYK2—multiple sclerosis	3.34e-06	1.29e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—TGFB1—multiple sclerosis	3.33e-06	1.29e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IL2—multiple sclerosis	3.32e-06	1.28e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MMP9—multiple sclerosis	3.32e-06	1.28e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—MAPK1—multiple sclerosis	3.29e-06	1.27e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—STAT3—multiple sclerosis	3.28e-06	1.26e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—MAPK1—multiple sclerosis	3.27e-06	1.26e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—POMC—multiple sclerosis	3.25e-06	1.25e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—STAT3—multiple sclerosis	3.25e-06	1.25e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—IL6—multiple sclerosis	3.24e-06	1.25e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—APOE—multiple sclerosis	3.21e-06	1.24e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—IL6—multiple sclerosis	3.19e-06	1.23e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CCL2—multiple sclerosis	3.18e-06	1.23e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MMP9—multiple sclerosis	3.14e-06	1.21e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—STAT3—multiple sclerosis	3.13e-06	1.21e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—MYC—multiple sclerosis	3.04e-06	1.18e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TGFB1—multiple sclerosis	3.04e-06	1.17e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—IL6—multiple sclerosis	3.02e-06	1.17e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—MYC—multiple sclerosis	3.02e-06	1.16e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TGFB1—multiple sclerosis	3.01e-06	1.16e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IL2—multiple sclerosis	2.99e-06	1.16e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—MAPK1—multiple sclerosis	2.98e-06	1.15e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—STAT3—multiple sclerosis	2.95e-06	1.14e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—MAPK1—multiple sclerosis	2.95e-06	1.14e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—IL6—multiple sclerosis	2.95e-06	1.14e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IL2—multiple sclerosis	2.93e-06	1.13e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TYK2—multiple sclerosis	2.89e-06	1.11e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—STAT3—multiple sclerosis	2.89e-06	1.11e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—IL6—multiple sclerosis	2.87e-06	1.11e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—MAPK1—multiple sclerosis	2.84e-06	1.1e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MMP9—multiple sclerosis	2.83e-06	1.09e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—STAT3—multiple sclerosis	2.8e-06	1.08e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—IL6—multiple sclerosis	2.79e-06	1.08e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL2—multiple sclerosis	2.78e-06	1.07e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MMP9—multiple sclerosis	2.77e-06	1.07e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—POMC—multiple sclerosis	2.76e-06	1.07e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MYC—multiple sclerosis	2.74e-06	1.06e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TGFB1—multiple sclerosis	2.74e-06	1.06e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—IL6—multiple sclerosis	2.73e-06	1.05e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IL6—multiple sclerosis	2.72e-06	1.05e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—APOE—multiple sclerosis	2.72e-06	1.05e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MAPK1—multiple sclerosis	2.69e-06	1.04e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—MYC—multiple sclerosis	2.68e-06	1.04e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—TGFB1—multiple sclerosis	2.68e-06	1.03e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL6—multiple sclerosis	2.66e-06	1.03e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL6—multiple sclerosis	2.65e-06	1.02e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MMP9—multiple sclerosis	2.63e-06	1.02e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—MAPK1—multiple sclerosis	2.62e-06	1.01e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MYC—multiple sclerosis	2.6e-06	1e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TGFB1—multiple sclerosis	2.59e-06	1e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MAPK1—multiple sclerosis	2.54e-06	9.81e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL6—multiple sclerosis	2.53e-06	9.75e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—STAT3—multiple sclerosis	2.52e-06	9.72e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—ALB—multiple sclerosis	2.52e-06	9.71e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—IL6—multiple sclerosis	2.51e-06	9.7e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—STAT3—multiple sclerosis	2.47e-06	9.52e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—BCHE—multiple sclerosis	2.43e-06	9.37e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL2—multiple sclerosis	2.4e-06	9.27e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—APOE—multiple sclerosis	2.37e-06	9.15e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MYC—multiple sclerosis	2.34e-06	9.04e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—STAT3—multiple sclerosis	2.34e-06	9.03e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—POMC—multiple sclerosis	2.34e-06	9.02e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TGFB1—multiple sclerosis	2.33e-06	9.01e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MYC—multiple sclerosis	2.29e-06	8.85e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MAPK1—multiple sclerosis	2.29e-06	8.84e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—IL6—multiple sclerosis	2.29e-06	8.83e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TGFB1—multiple sclerosis	2.29e-06	8.82e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MMP9—multiple sclerosis	2.27e-06	8.78e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—IL6—multiple sclerosis	2.27e-06	8.75e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MAPK1—multiple sclerosis	2.24e-06	8.65e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—APOE—multiple sclerosis	2.23e-06	8.62e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—APOE—multiple sclerosis	2.21e-06	8.54e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL6—multiple sclerosis	2.18e-06	8.43e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MYC—multiple sclerosis	2.17e-06	8.39e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TGFB1—multiple sclerosis	2.17e-06	8.37e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—ALB—multiple sclerosis	2.13e-06	8.22e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MAPK1—multiple sclerosis	2.13e-06	8.2e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IL6—multiple sclerosis	2.06e-06	7.96e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—POMC—multiple sclerosis	2.04e-06	7.86e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—STAT3—multiple sclerosis	2.02e-06	7.8e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—IL6—multiple sclerosis	2.02e-06	7.78e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IL6—multiple sclerosis	1.95e-06	7.54e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—POMC—multiple sclerosis	1.92e-06	7.4e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—POMC—multiple sclerosis	1.9e-06	7.34e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MYC—multiple sclerosis	1.88e-06	7.25e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TGFB1—multiple sclerosis	1.87e-06	7.23e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—ALB—multiple sclerosis	1.86e-06	7.16e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MAPK1—multiple sclerosis	1.84e-06	7.09e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IL6—multiple sclerosis	1.76e-06	6.79e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ALB—multiple sclerosis	1.75e-06	6.75e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ALB—multiple sclerosis	1.73e-06	6.69e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IL6—multiple sclerosis	1.72e-06	6.65e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL6—multiple sclerosis	1.63e-06	6.3e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—APOE—multiple sclerosis	1.46e-06	5.63e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL6—multiple sclerosis	1.41e-06	5.45e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—POMC—multiple sclerosis	1.25e-06	4.84e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ALB—multiple sclerosis	1.14e-06	4.41e-06	CbGpPWpGaD
